the float is minuscule...violent swings in price per share are to be expected....my Magic-8 ball says compare this chart to that of IRG for what's in store technically.
The last 10-K was a laundry list of screw ups. That being said, it's pretty hard to lose money in the insurance business. The Phoenix shall rise again. The institutional investors are obviously fleeing at the moment, signaling their thoughts about the current CEO... The BoD is asleep at the wheel.
That is what you call a "game changer."
Sentiment: Strong Buy
One more piece of the deal has to be put in place but it shouldn't be too difficult. I'm expecting major news in in two to four weeks.
Your families will be able to salvage some money by harvesting your organs thanks to Cytosorb!
Kellum JA, Venkataraman R, Powner D, Elder M, Hergenroeder G, Carter M.
Feasibility study of cytokine removal by hemoadsorption in brain-dead humans.
Crit Care Med. 2008 Jan;36(1):268-72.
Tssk. Tssk. You're conflating things. There is doubt about the timing of the widespread adoption and sales not their inevitability or the science underlying this groundbreaking technology.
ctso4life: I'm not sure why we're arguing. Yes, the evidence to date in anecdotal, and, yes, anecdotal evidence is the weakest. A single stick is weak too but when bundled to other sticks, the bundle is quite strong. So it is with anecdotal evidence. Personally, I am amazed by the number of positive case reports to date .... indeed, it seems as if they are beginning to become a torrent. These positive reports are even more amazing given that doctors have mostly been reporting upon their most hopeless patients. Of course, I agree with you, that Cytosorb won't become a blockbuster, de rigeur technology until the clinical trials are published.
The animal studies were promising. Now, the case reports are promising. Is there any doubt that the clinical reports won't be the same?
is there any doubt that the sales of Cytosorb will climb to the tens or hundreds of millions when that inevitability happnen?
I'm sure there's more shorts now but I doubt they're big hedge funds. You would have to be a complete ignoramus to short a low float stock with such explosive potential. Positive reports from a clinical trial would rocket CTSO to $20 and beyond. More and more cutting edge doctors will be trying Cytosorb with positive results but the vast majority of doctors are sheep. When clinical trials are reported, only then, the sheep will stampede to buy Cytosorb.
Many are complaining about the slowness of the clinical trials...this does not surprise me. Many maladies give rise to cytokine storms so the age and health (and, hence, the various titers) of the patients varies greatly. Cytokine storms are very messy from a pharmaco-physiological perspective. Different factors (e.g., the various interleukins) are spiking and crashing. Clinicians will want a specific titer number to which they can refer as to when Cytosorb should be applied. A single clinical study that provides that specific titer value will cause sales to rocket. If a doctor gets sued, he or she can comfortably refer that the number. Remember the technology works and it is needed. Eventually, a new era in the treatment of sepsis will occur (and when (not if) that happens, it will occur very rapidly).
There are now 10 case reports published (or in poster form) that show that Cytosorb works as advertised...it dramatically mitigates cytokine storms. There is even evidence that it has saved lives that otherwise would have been lost. Why, therefore, have sales been poor?
Sales have been poor because doctors, although they are excited by the prospect, don't know when to use it. There has been no independent clinical studies showing that when "Factor X" reaches a certain level, Cytosorb is indicated for use. There is little knowledge about how often the filters have to be replaced or when treatment can be curtailed. Cytosorb is a tool that acts like a drug in that it causes rapid changes to blood chemistry but it has not been tested as rigorously as a drug. Currently, the major treatments for sepsis include antibiotics but it is not clear the extent to which the filter removes antibiotics. This necessitates frequent monitoring of drug levels.
Right now, intensivists are only using Cytosorb for their most difficult cases, and they have reported successes in the form of case reports. Conservative doctors and those who are risk-shy are not adopting Cytosorb because it is not been properly tested in a clinical setting.
What does the future hold? As word gets out, more doctors will try Cytosorb on their most dire patients, and they will have success. The number of positive case reports and the numbers of lives saved will continue to grow. Doctors may start to use it on less and less dire patients. Sales will pick up mildly. Clinical trials will also eventually be completed, and there is little reason to believe that they, too, won't be positive. Once the stamps of approval come from the clinical trials, then there will be a frenzy of purchasing.
This week is the week to buy. Don't listen to the naysayers who say the technology doesn't work. It does. Greater knowledge will lead to exponential adoption. This is the beginning of a new era.